Therefore, the regulation of histone acetylation, especially the activation of SIRT1, is a feasible target for the generation of new anti-inflammatory therapies, and the future targeted activation of SIRT1 is expected to become a potential treatment for non-infectious diseases such as BD-related uveitis. Here, SIRT1 is linked to Behcet disease.